Oral delivery of dihydroartemisinin for the treatment of melanoma via bovine milk exosomes
Drug Delivery and Translational Research · 2025-08 · 15 (8) · 2862-2877
DOI: 10.1007/s13346-024-01785-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Delivery and Translational Research, online erschienen am 07.01.2025. Verfasst von Dulla Naveen Kumar und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Engineering and Technology, Indian Institute of Technology (BHU), Varanasi, 221005, Uttar Pradesh, India. Hauptthemen laut MEDLINE: Exosomes, Artemisinins, Antineoplastic Agents, Milk. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Science and Engineering Research Board.
Abstract (Originalsprache)
Cancer, particularly skin cancer, is a major cause of mortality worldwide, with melanoma being one of the most aggressive and challenging to treat types. Current therapeutic options, such as dacarbazine (DTIC), have limitations due to dose-related toxicities like liver toxicity. Therefore, there is a need for new and effective treatments for melanoma. Dihydroartemisinin (DHA), derived from artemisinin compounds known for their anti-malarial properties, has shown promise as an anti-cancer agent. However, the clinical use of DHA faces challenges such as low solubility and toxicity, which limit its therapeutic efficacy. To overcome these challenges, we developed an exosomal formulation of DHA to enhance its anti-cancer activity and reduce metastasis. Exosomes, biological vesicles, contain many biological macromolecules such as DNA, RNAs, and many other proteins, involved in intercellular communication, were isolated and loaded with DHA using the sonication method. The loaded exosomes were characterized for size (90-103 nm), polydispersity index (PDI: 0.119-0.123), and zeta potential (-23 to -28 mV). In vitro studies demonstrated the efficacy of DHA-loaded exosomes through cytotoxicity and apoptosis assays. The molecular mechanism of action was further elucidated using immunoblotting analysis, focusing on key proteins involved in apoptosis and metastasis regulation, including Bax, Bcl-2, survivin, and MMP-9. Furthermore, we observed a significant improvement in oral bioavailability (2.8-fold) with the exosomal formulation and enhanced in vivo anti-cancer activity of DHA. Notably, treatment with Exo-DHA resulted in strong enhancement of tumor growth suppression and reduced melanoma cell metastasis compared to free DHA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Engineering and Technology, Indian Institute of Technology (BHU), Varanasi, 221005, Uttar Pradesh, India.
- Department of Oncology, University of Alberta, Edmonton, AB, T6G 1Z2, Canada.
- Cross Cancer Institute, Edmonton, AB, T6G 1Z2, Canada.
- Department of Pharmaceutical Engineering and Technology, Indian Institute of Technology (BHU), Varanasi, 221005, Uttar Pradesh, India. ashish.phe@itbhu.ac.in.
ORCID-Profile: Ashish Kumar Agrawal
Förderung
- Science and Engineering Research Board
Zitieren
APA
Kumar, D. N., Chaudhuri, A., Dehari, D., Gamper, A. M., Kumar, D., & Agrawal, A. K. (2025). Oral delivery of dihydroartemisinin for the treatment of melanoma via bovine milk exosomes. Drug Delivery and Translational Research, 15(8), 2862-2877. https://doi.org/10.1007/s13346-024-01785-6
Vancouver
Kumar DN, Chaudhuri A, Dehari D, Gamper AM, Kumar D, Agrawal AK. Oral delivery of dihydroartemisinin for the treatment of melanoma via bovine milk exosomes. Drug Delivery and Translational Research. 2025;15(8):2862-2877. doi:10.1007/s13346-024-01785-6
BibTeX
@article{Kumar2025,
author = {Kumar, Dulla Naveen and Chaudhuri, Aiswarya and Dehari, Deepa and Gamper, Armin M and Kumar, Dinesh and Agrawal, Ashish Kumar},
title = {Oral delivery of dihydroartemisinin for the treatment of melanoma via bovine milk exosomes},
journal = {Drug Delivery and Translational Research},
year = {2025},
volume = {15},
number = {8},
pages = {2862--2877},
doi = {10.1007/s13346-024-01785-6}
}
EUVIMED